JP2021533134A5 - - Google Patents
Info
- Publication number
- JP2021533134A5 JP2021533134A5 JP2021505847A JP2021505847A JP2021533134A5 JP 2021533134 A5 JP2021533134 A5 JP 2021533134A5 JP 2021505847 A JP2021505847 A JP 2021505847A JP 2021505847 A JP2021505847 A JP 2021505847A JP 2021533134 A5 JP2021533134 A5 JP 2021533134A5
- Authority
- JP
- Japan
- Prior art keywords
- conhch
- och
- group
- cells
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862713823P | 2018-08-02 | 2018-08-02 | |
| US62/713,823 | 2018-08-02 | ||
| PCT/US2019/044421 WO2020028532A1 (en) | 2018-08-02 | 2019-07-31 | Adjuvant effect of the tlr1/2 agonist diprovocim synergizes with checkpoint-inhibiting antibodies to eliminate disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021533134A JP2021533134A (ja) | 2021-12-02 |
| JP2021533134A5 true JP2021533134A5 (enExample) | 2022-09-22 |
Family
ID=69232110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505847A Pending JP2021533134A (ja) | 2018-08-02 | 2019-07-31 | チェックポイント阻害抗体と相乗効果を示し、疾患を排除するｔｌｒ１／２アゴニストジプロボッシムのアジュバント効果 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210315992A1 (enExample) |
| EP (1) | EP3829571B1 (enExample) |
| JP (1) | JP2021533134A (enExample) |
| KR (1) | KR20210029280A (enExample) |
| CN (1) | CN113164445A (enExample) |
| AU (2) | AU2019315952A1 (enExample) |
| BR (1) | BR112021001992A2 (enExample) |
| CA (1) | CA3108515A1 (enExample) |
| IL (1) | IL280584B2 (enExample) |
| WO (1) | WO2020028532A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11938182B2 (en) | 2020-03-26 | 2024-03-26 | Provectus Pharmatech, Inc. | Halogenated xanthenes as vaccine adjuvants |
| EP4103283A4 (en) | 2020-03-26 | 2024-02-28 | Provectus Pharmatech, Inc. | NEW USES OF HALOGENATED XANTHENES IN ONCOLOGY AND VIROLOGY |
| CN115666553A (zh) * | 2020-05-27 | 2023-01-31 | 轴向治疗公司 | Tlr2调节剂化合物及其药物组合物和用途 |
| US20230210925A1 (en) * | 2020-07-14 | 2023-07-06 | Dic Corporation | Composition for cytotoxic t lymphocyte (ctl) activation |
| WO2023212650A1 (en) * | 2022-04-29 | 2023-11-02 | The Scripps Research Institute | Next generation diprovocims that activate the innate and adaptive immune response |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US5180806A (en) | 1988-05-16 | 1993-01-19 | The Scripps Research Institute | Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods |
| US6489354B1 (en) | 1999-03-02 | 2002-12-03 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| US6942866B2 (en) | 2000-08-16 | 2005-09-13 | Apovia, Inc. | Malaria immunogen and vaccine |
| ATE361068T1 (de) * | 2001-08-08 | 2007-05-15 | Pentraxin Therapeutics Ltd | Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| US20090081157A1 (en) * | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
| CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP3177601B1 (en) * | 2014-08-06 | 2023-03-01 | The Scripps Research Institute | Tlr-independent small molecule adjuvants |
| CN107427567A (zh) * | 2015-01-29 | 2017-12-01 | 宾夕法尼亚大学理事会 | 检查点抑制剂和疫苗组合物及其用于免疫疗法的用途 |
| MX2017012939A (es) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| CR20180519A (es) * | 2016-03-31 | 2019-03-05 | Neon Therapeutics Inc | Neoantígenos y métodos de su uso |
| JP6964298B2 (ja) * | 2016-06-29 | 2021-11-10 | ザ スクリプス リサーチ インスティテュート | ジプロボシム：新規かつ強力なクラスのｔｌｒアゴニスト |
| US20180088749A1 (en) | 2016-09-26 | 2018-03-29 | Uber Technologies, Inc. | Customized content generation for a user interface for a network service |
| US20180169224A1 (en) * | 2016-12-12 | 2018-06-21 | Wisconsin Alumni Research Foundation | Tlr agonists for reducing activation-induced pd-1 expression on t cells and methods of use |
-
2019
- 2019-07-31 BR BR112021001992-8A patent/BR112021001992A2/pt unknown
- 2019-07-31 IL IL280584A patent/IL280584B2/en unknown
- 2019-07-31 AU AU2019315952A patent/AU2019315952A1/en not_active Abandoned
- 2019-07-31 JP JP2021505847A patent/JP2021533134A/ja active Pending
- 2019-07-31 WO PCT/US2019/044421 patent/WO2020028532A1/en not_active Ceased
- 2019-07-31 CN CN201980065609.8A patent/CN113164445A/zh active Pending
- 2019-07-31 EP EP19844778.1A patent/EP3829571B1/en active Active
- 2019-07-31 CA CA3108515A patent/CA3108515A1/en active Pending
- 2019-07-31 KR KR1020217006180A patent/KR20210029280A/ko not_active Ceased
- 2019-07-31 US US17/265,333 patent/US20210315992A1/en active Pending
-
2025
- 2025-06-03 AU AU2025204146A patent/AU2025204146A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2870679T3 (es) | Compuesto de pirimidina | |
| UY39890A (es) | Compuestos con diana en mutante de p53 | |
| JP2006507265A5 (enExample) | ||
| JP2017502994A5 (enExample) | ||
| RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
| JP2013532132A5 (enExample) | ||
| EA200400617A1 (ru) | Гетероариламины в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3) | |
| JP2021532162A5 (enExample) | ||
| JP2014515406A5 (enExample) | ||
| GB2434367A (en) | Improved vaccines | |
| EA202191315A1 (ru) | Катионные липиды, содержащие кремний | |
| AR105194A1 (es) | Anticuerpos anti-cd123 y conjugados y derivados de estos | |
| JP2017526704A5 (enExample) | ||
| Chua et al. | Inactivated influenza vaccine that provides rapid, innate-immune-system-mediated protection and subsequent long-term adaptive immunity | |
| JP2009504803A (ja) | Ｔｌｒアゴニスト | |
| JP2015518055A5 (enExample) | ||
| JP2015520143A5 (enExample) | ||
| JP2018511628A5 (enExample) | ||
| JP2019529518A5 (enExample) | ||
| BR112013031028A2 (pt) | conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles | |
| JP2013540292A5 (enExample) | ||
| AR095575A1 (es) | Inhibidores de la proliferación celular y conjugados de los mismos | |
| KR20190030693A (ko) | 히스톤 아세틸트랜스퍼라제 활성화제 및 이의 조성물 및 용도 | |
| JP2012532883A5 (enExample) | ||
| Hu et al. | A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model |